Tag: Karxt

For over 30 years, there have been no new classes of medication for treating psychosis, a long-standing challenge for patients and clinicians. The recent FDA approval of Cobenfy, formerly KarXT, marks a significant milestone by introducing a novel mechanism to address the complex symptoms of psychosis. This provides a new answer to the question, **what is the new drug for psychosis?**

An estimated 24 million people worldwide live with schizophrenia, but only 31.3% receive specialist mental health care [1.7.1]. For them, the answer to 'What is the new schizophrenia pill?' is a recently approved drug called Cobenfy, representing a major therapeutic advance.

Affecting approximately 24 million people worldwide, schizophrenia is a serious mental disorder where treatment has long been dominated by similar-acting drugs [1.6.2]. So, what is the new medication for schizophrenia? The answer lies in a novel class of drugs, led by the recently FDA-approved Cobenfy (xanomeline-trospium) [1.2.3].

In clinical trials, approximately 19% of patients taking xanomeline/trospium (Cobenfy) reported nausea as a common side effect. Understanding what are the side effects of xanomeline, which is combined with trospium to mitigate some adverse reactions, is crucial for anyone considering or currently on this novel antipsychotic medication.

Worldwide, over 20 million people live with schizophrenia, yet up to 30% of patients do not respond well to traditional treatments [1.2.4, 1.6.2]. So, is xanomeline an antipsychotic? Yes, it represents the first in a new class of antipsychotics with a novel mechanism of action [1.2.1, 1.3.3].

According to clinical trials, Cobenfy significantly reduced the severity of schizophrenia symptoms in adults within five weeks. **How does Cobenfy make you feel?** The medication can alleviate positive symptoms like hallucinations and delusions, while also addressing negative symptoms such as emotional flatness or lack of motivation.

For the first time in decades, a new class of antipsychotic medication was approved by the FDA in September 2024. This groundbreaking drug, Cobenfy (formerly known as KarXT), offers a novel mechanism of action, presenting a new therapeutic option for adults with schizophrenia.

For decades, negative symptoms in schizophrenia have been notoriously difficult to treat, with traditional antipsychotics primarily targeting positive symptoms. A major development in this field is the FDA approval of Cobenfy (KarXT) in 2024, raising the question: what is the new antipsychotic for negative symptoms and how does it work differently?.

In September 2024, the FDA approved the first new class of antipsychotic medications in decades, containing the active muscarinic agonist **xanomeline**. This oral medication, marketed as Cobenfy, represents a significant paradigm shift by targeting cholinergic receptors to treat schizophrenia in adults.

Recent research indicates that schizophrenia spectrum disorders are more common than previously thought, affecting approximately 1.8% of U.S. adults [1.8.1]. For them, the critical question is often, **what is the new drug for schizophrenia?** The latest answer marks a significant breakthrough in treatment.